I wanted to make sure you saw our previous email about the Early Bird Rate ending for the Fierce Biotech Summit. Prices increase tonight at midnight and only 8 passes are left at this rate. Don't wait to secure your spot! Register now and save $346 on your registration.*
I look forward to seeing you in October!
Best regards,
Michelle Benz
Conference Production Director
Fierce Life Sciences |
|
|
LAST CHANCE TO SAVE $346!* |
|
|
In less than two months, the Fierce Biotech Summit will be returning to Boston on October 16-18th and a who's who in Biotech will be coming together to share their experiences, insights and thoughts on the future of biotech. Brought to you by the editors behind Fierce Biotech, this three-day event will cover the use of AI in drug development, unique dealmaking strategies, the latest innovations in oncology and much more with two tracks dedicated to Early Stage Development and Strategy and Dealmaking. VIEW THE AGENDA>> The deadline for the Early Bird Rate is August 28th and limited passes are left at that rate. Don't wait to secure your spot and register now to save up to $346! |
*Only 25 passes available at this rate. Early Bird Rate is only valid for qualified pharma, biotech and medical device companies and legal or consulting firms. |
|
|
FEATURED SPEAKERS: - Joseph Panetta, President & CEO, Biocom California
- Nicholas Galakatos, Ph.D., Global Head of Life Sciences, Blackstone Life Sciences
- Marianne De Backer, M.Sc., Ph.D., MBA, CEO, Vir Biotechnology, Inc.
- Alice Zhang, CEO and Co-founder, Verge Genomics
- Devyn Smith, CEO, Arbor Biotechnologies, and Chairman of ARM
- Rachel King, CEO, Biotechnology Innovation Organization (BIO)
- Priya Singhal, MD, MPH, EVP, Head of Development, Biogen
- Jeremy Levin, CEO and Chairman, Ovid Therapeutics
- Mathai Mammen, CEO, FogPharma
- Thaminda Raminyake, M.S., MBA, Chief Business Officer, Affini-T Therapeutics
- Peter Pitts, President, Center for Medicine in the Public Interest, and Former FDA Associate Commissioner
- Amanda Banks, M.D., Former CEO, Blackfynn
- Maha Radhakrishnan, M.D., Group SVP and Chief Medical Officer, Biogen
- Nadim Ahmed, President and CEO, Cullinan Oncology
|
ESSENTIAL TOPICS YOU DON'T WANT TO MISS: The Next Blockbuster Indications The Inflation Reduction Act (IRA): The Dawn of a New Era - What Will it Mean for Innovation? Success in the Middle of a Downturn: Strategies for Weathering the Biotech Storm and Building Trust in the Market The Future of Oncology: Innovation and Advancements in the Biotech Industry Revolutionizing Drug Discovery and Development with AI: Maximizing Efficiency and Innovation in Biotech Fierce 15 Panel – Where are they now?
|
|
|
Learn About Partnership Opportunities |
|
|
600+ Senior Biotech Executives |
| 64% Attendees from Biotech & Pharma |
| | |
|
Position your company as a thought leader, promote your brand and engage with leading Biotech Executives. Contact us today to learn why the Fierce Biotech Summit is the right show for you! |
| |
|
| Maximize learning by attending as a group and save 25% or more |
|
|
Book Your Stay Now at the Discounted Rate! |
|
|
The Westin Boston Seaport District
425 Summer Street
Boston, MA 02210
Deadline: September 22, 2023 |
| |
|
Thank You to Our 2023 Partners |
|
|
If you no longer wish to receive promotion on this event, simply unsubscribe.
Refer to our Privacy Policy.
Fierce Life Sciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017 Contact Us
© 2023 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission. |
|
|
|
